BBT-877: Possible Treatment for Idiopathic Pulmonary Fibrosis Request More Information Trial Objective Idiopathic pulmonary fibrosis (IPF) currently affects millions of people globally, and current treatments such as pirfenidone or nintedanib are often poorly tolerated in some patients due to frequently associated side effects. Researchers want to know if an investigational medication called BBT-877, either alone or in conjunction with other therapies, may help slow lung function decline. In this study, participants 40 and older with IPF will receive either BBT-877 or the placebo that does not contain any medication twice a day. Enrollment Active Clinical Trials Currently Recruiting Who Can Participate Adults aged 40 and older with a documented IPF diagnosis, who are not current smokers and do not have a history of conditions that increase risk (prior lung transplant, pulmonary hypertension, immunosuppressive condition or congestive heart failure). Participants must not be taking background antifibrotic medication, or they must have been on an antifibrotic (nintedanib or pirfenidone) for at least three months. Age: 40+ Gender: Any Gender Estimated Time Commitment Six clinic visits over up to 34 weeks × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Provided Travel Reimbursement: Available Trial Contact For more information, contact: Elizabeth Del Real 303-398-1172 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors Bridge Biotherapeutics, Inc Principal Investigators Jeff Swigris, DO, MS + × Jeff Swigris, DO, MS Professor Department of Medicine Division of Pulmonary, Critical Care & Sleep Medicine View Full Profile Make an Appoinment Request More Information By completing this form, you agree to learn more about this study and see if you qualify. First Name:* Last Name:* Email Address:* Phone:* I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: YesNo
Trial Objective Idiopathic pulmonary fibrosis (IPF) currently affects millions of people globally, and current treatments such as pirfenidone or nintedanib are often poorly tolerated in some patients due to frequently associated side effects. Researchers want to know if an investigational medication called BBT-877, either alone or in conjunction with other therapies, may help slow lung function decline. In this study, participants 40 and older with IPF will receive either BBT-877 or the placebo that does not contain any medication twice a day.